First-line Therapy Study of untreated advanced or metastatic Renal Cell Cancer A Phase III Trial of pro-active Therapy Monitoring during the Treatment with Sunitinib or Pembrolizumab in combination with Axitinib or Avelumab in Combination with Axitinib for Patients with advanced or metastatic Renal Cell Cancer (PREPARE) - AUO Study AN 49/18